|
ZBTB33 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.30130350939339E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.00089936339032E-11 |
| Normal-vs-Stage2 |
2.661600E-03 |
| Normal-vs-Stage3 |
7.23300000005089E-07 |
| Normal-vs-Stage4 |
1.007880E-04 |
| Stage1-vs-Stage2 |
2.663600E-01 |
| Stage1-vs-Stage3 |
2.353600E-01 |
| Stage1-vs-Stage4 |
3.614400E-01 |
| Stage2-vs-Stage3 |
7.887000E-01 |
| Stage2-vs-Stage4 |
8.338200E-01 |
| Stage3-vs-Stage4 |
9.798800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.77849956983778E-10 |
| Normal-vs-AfricanAmerican |
1.381700E-04 |
| Normal-vs-Asian |
7.14559999948072E-07 |
| Caucasian-vs-AfricanAmerican |
6.982100E-02 |
| Caucasian-vs-Asian |
3.099200E-01 |
| AfricanAmerican-vs-Asian |
3.689400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.53130000019242E-07 |
| Normal-vs-Female |
1.11129994095904E-11 |
| Male-vs-Female |
2.926200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.33010327383477E-11 |
| Normal-vs-Age(41-60Yrs) |
2.60400001561578E-09 |
| Normal-vs-Age(61-80Yrs) |
3.5211000000035E-05 |
| Normal-vs-Age(81-100Yrs) |
3.244200E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.399000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.048760E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.241770E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.567200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.850390E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.226400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.350000E-01 |
| Classical-VS-Follicular |
2.223200E-04 |
| Classical-VS-Other |
2.505400E-01 |
| Classical-VS-Normal |
1.67399427652981E-12 |
| Tall-VS-Follicular |
1.825840E-01 |
| Tall-VS-Other |
5.057600E-01 |
| Tall-VS-Normal |
4.233000E-04 |
| Follicular-VS-Other |
9.340800E-01 |
| Follicular-VS-Normal |
7.224600E-03 |
| Other-VS-Normal |
3.544200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.15810000267791E-08 |
| Normal-vs-N1 |
4.816100E-04 |
| N0-vs-N1 |
9.192600E-01 |
|
|
